Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.37 |
| ▸ | FEN1 | P39748 | 2/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2129498 | 1.00 | CYP3A4 (0.38) | CYP3A4ALOX5APFEN1LOXL2DHFR | |
| SCHEMBL2128556 | 0.84 | CYP3A4 (0.43) | CYP3A4ALOX5APFEN1LOXL2DHFR | |
| SCHEMBL2128560 | 0.84 | CYP3A4 (0.43) | CYP3A4ALOX5APFEN1LOXL2DHFR | |
| SCHEMBL12678842 | 0.84 | CYP3A4 (0.39) | CYP3A4ALOX5APFEN1LOXL2DHFR | |
| SCHEMBL2128540 | 0.81 | CYP3A4 (0.47) | CYP3A4ALOX5APFEN1LOXL2PTGES2 | |
| SCHEMBL2128538 | 0.81 | CYP3A4 (0.47) | CYP3A4ALOX5APFEN1LOXL2PTGES2 | |
| SCHEMBL1543153 | 0.81 | CYP3A4 (0.59) | CYP3A4 | |
| SCHEMBL1543150 | 0.81 | CYP3A4 (0.59) | CYP3A4 | |
| SCHEMBL1542893 | 0.79 | ERN1 (0.42) | CYP3A4ALOX5APFEN1LOXL2PTGES2 | |
| SCHEMBL1542276 | 0.77 | ALOX5AP (0.43) | ALOX5APFEN1LOXL2DHFRPTGES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273773-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2307372-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2012-04-25 | — | — | EP | disclosed |
| US-20100021423-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100021423-A1 | Heterocyclic antiviral compounds | POLR2A, RRM2B, RRP1B | CYP3A4 528/4885ALOX5AP 3584/4885FEN1 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.